Related Experiment Video
Updated: May 22, 2026
11:49
Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model
Published on: September 9, 2011
Endothelial progenitor cell capture stent: safety and effectiveness
1Cardiac Department, National University Heart Centre, Singapore.
Journal of Interventional Cardiology
|May 23, 2012
Summary
Endothelial progenitor cell (EPC) capture stents promote healing but require larger trials to confirm effectiveness. A novel Combo stent combines EPC capture with sirolimus elution to improve restenosis reduction.
Area of Science:
- Cardiovascular research
- Biomaterials science
- Medical device innovation
Background:
- Endothelial progenitor cells (EPCs) aid arterial healing.
- EPC capture stents utilize anti-human CD34 antibodies to attract circulating EPCs to injured sites.
- This technology aims to accelerate healing, reducing restenosis and stent thrombosis.
Purpose of the Study:
- To evaluate the safety and efficacy of EPC capture stents.
- To address the limitations of early EPC capture stents, particularly in comparison to drug-eluting stents.
- To introduce and assess the novel Combo stent, integrating EPC capture with sirolimus elution.
Main Methods:
- Review of existing registry and postmarketing studies on EPC capture stents.
- Analysis of angiographic data regarding in-stent late loss.
- Introduction of the Combo stent, a bioengineered sirolimus-eluting stent combining EPC capture technology.
- Presentation of preliminary data from animal studies and first-in-man trials of the Combo stent.
Main Results:
- EPC capture stents demonstrate a good safety profile based on initial studies.
- In-stent late loss with EPC capture stents (0.7-0.9 mm) appears less favorable than with drug-eluting stents.
- Animal studies for the Combo stent have yielded encouraging results.
- The first-in-man study of the Combo stent has been completed.
Conclusions:
- While EPC capture stents show promise for accelerated healing, large-scale randomized trials are needed to definitively establish their effectiveness against bare metal and drug-eluting stents.
- The Combo stent represents a promising advancement, merging EPC capture with sirolimus elution to potentially enhance restenosis reduction while preserving pro-healing properties.
